Peptide Therapy Near Me: How to Find a Verified Local Provider
Find peptide therapy near you: 2,200+ verified US providers across 52 states, including telehealth platforms for states with limited local access.
Founder & CEO, PeptideBase
Alexandre Peterson is the founder of PeptideBase, an independent provider directory and educational research platform for the peptide space. He built PeptideBase to bring structure and transparency to a fragmented market — systematically indexing 2,700+ providers, mapping 100+ peptides, and creating tools that help researchers find the right starting point.
PeptideBase is an independent project. All content is educational and informational — no medical advice framing, no dosing guidance, no clinical recommendations.
Find peptide therapy near you: 2,200+ verified US providers across 52 states, including telehealth platforms for states with limited local access.
GLP-1 agonists, GH-releasing peptides, and growth hormone fragments studied for fat loss — research summaries and verified US providers.
The PeptideBase directory lists 3,136 active providers. Here's exactly what we check — and what we don't — before we assign a verified badge.
PeptideBase analyzed 545+ longevity providers to identify the signals that separate credible DeSci research projects from noise. Here's the framework.
BPC-157 isn't federally scheduled, but FDA classifies it as an unapproved drug. State rules vary. Two supply chains, 500+ US providers — full 2026 state-by-state breakdown.
An eight-step checklist for vetting peptide providers — licensing lookups, COA verification, telehealth evaluation, and the red flags that should stop the process.
7 questions. Matched to vetted peptide providers filtered by goals, location, and health background. How the PeptideBase matching algorithm works.
503A pharmacies compound per prescription. 503B are FDA-registered outsourcing facilities. What the difference means for peptide sourcing in 2026.
TB-500 mimics Thymosin Beta-4 — studied for tissue repair and recovery in animal models. Covers mechanism, evidence quality, and US provider availability.
PT-141 targets brain melanocortin receptors — distinct from PDE5 inhibitors. Research summary on bremelanotide, evidence quality, and US provider data.
A third-party COA is the minimum bar. What HPLC purity, mass spec confirmation, and batch traceability actually mean for research peptide vendors.
How to find a legitimate 503A compounding pharmacy for peptides: what to verify, what to ask about sterile compounding, and red flags to watch for.
Semaglutide and tirzepatide compared on mechanism, clinical trial outcomes, and 2026 compounding pharmacy availability in the US.
NAD+ declines with age. What peer-reviewed research shows about supplementation, NR vs NMN precursors, and where the longevity evidence actually stands.
30 years of animal research on BPC-157 — mechanisms, evidence quality, and what's confirmed vs. commonly claimed about this recovery peptide.
Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.
Prices, providers, and published evidence — tracked independently, never an affiliate code. Get research updates as the data grows.
Free · occasional research updates only · unsubscribe in one click
Already a member? Sign in